<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02853643</url>
  </required_header>
  <id_info>
    <org_study_id>ASN002-102</org_study_id>
    <nct_id>NCT02853643</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Study to Evaluate Pharmacokinetics and Food-Effect in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-Effect in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asana BioSciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asana BioSciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability, and determine the blood
      levels (pharmacokinetics), in both a fed and fasted condition, of a single dose of ASN002.
      Healthy volunteers will be participants in the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects reporting adverse events during the study</measure>
    <time_frame>Days 1-28</time_frame>
    <description>Safety and tolerability will be determined by the number of subjects reporting adverse events during the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Days 1-6</time_frame>
    <description>Calculate Area under the plasma concentration time curve (AUC) from time 0 to infinity after first dose. AUC from time 0 to the time of last measured concentration. AUC from time 0 to 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) under fed and fasted conditions</measure>
    <time_frame>Days 1-6</time_frame>
    <description>Calculate Area under the plasma concentration time curve (AUC) from time 0 to infinity after first dose. AUC from time 0 to the time of last measured concentration. AUC from time 0 to 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration of ASN002</measure>
    <time_frame>Days 1-6</time_frame>
    <description>Calculate observed maximum plasma concentration after a dose and observed maximum plasma concentration at steady state. The time to reach the peak plasma concentration. The time to reach the peak plasma concentration at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration of ASN002 under fed and fasted conditions</measure>
    <time_frame>Days 1-6</time_frame>
    <description>Calculate observed maximum plasma concentration after a dose and observed maximum plasma concentration at steady state. The time to reach the peak plasma concentration. The time to reach the peak plasma concentration at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug half life of ASN002</measure>
    <time_frame>Days 1-6</time_frame>
    <description>Calculate terminal elimination rate constant and terminal half-life of ASN002</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug half life of ASN002 under fed and fasted conditions</measure>
    <time_frame>Days 1-6</time_frame>
    <description>Calculate terminal elimination rate constant and terminal half-life of ASN002</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>25 mg Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 25 mg ASN002</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 50 mg ASN002</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg Food effect cross over</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg single dose under both fasted and fed conditions in a cross over fashion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASN002</intervention_name>
    <description>Single dose study with food effect</description>
    <arm_group_label>25 mg Dose</arm_group_label>
    <arm_group_label>50 mg Dose</arm_group_label>
    <arm_group_label>100 mg Food effect cross over</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female, non-smoking subjects.

          2. Willing to use contraception throughout the duration of the study and for 90 days
             after the study.

          3. Capable of consent.

        Exclusion Criteria:

        Subjects to whom any of the following applies will be excluded from the study:

          1. Any clinically significant abnormality, infection, exposure to infection, recent live
             virus vaccination, or abnormal laboratory test results found during medical screening.

          2. History of alcohol or drug abuse, or a positive urine drug screen or breath alcohol
             test at screening.

          3. History of allergic reactions to protein kinase inhibitors, or significant allergic
             reactions to any drug.

          4. Positive pregnancy test at screening.

          5. Clinically significant ECG abnormalities.

          6. Participation in a clinical research study involving the administration of an
             investigational or marketed drug or device within 30 days prior to the first dosing,
             administration of a biological product in the context of a clinical research study
             within 90 days prior to the first dosing, or concomitant participation in an
             investigational study involving no drug or device administration.

          7. Use of medication other than topical products without significant systemic absorption:

          8. Donation of plasma within 7 days prior to dosing, or significant blood loss within the
             past 56 days.

          9. Subject is pregnant, or breast feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Wyatt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>InVentiv Health Clinical Research Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>InVentiv Health</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2016</study_first_submitted>
  <study_first_submitted_qc>July 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2016</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

